Immunogenicity and Tolerance Seminar (updated)

UPDATE:
Here are commemorative photos from our event. Thank you to all the speakers and participants for making the 2016 seminar a success. See you next year!

Click to see full image

EpiVax has taken the lead on the 2nd seminar on Immunogenicity and Tolerance on October 24th, 2016. The conference agenda is shown below.

What: Immunogenicity and Tolerance Seminar
When: Monday, October 24th, 2016
Where: Hilton Apollolaan
Cost: €75.00 (covers the food/venue – this is a not-for-profit event)

This meeting focused on the determinants of immunogenicity – a key feature of effective vaccines and a key barrier to success in the clinic for protein therapeutics. Conversely, tolerance induction is a key feature of successful protein therapeutics, while suppressing immune responses to vaccines. The reduction of T cell epitopes and introduction of Treg epitopes (like Tregitopes) for protein therapeutics, and the reverse process for vaccines, will be discussed and illustrated in case studies.

Congratulations to Marieke Van Ham, PhD for the Most Innovative Research Program or Product!

Presentations also included:

Elly Van Riet, PhD
Intravacc
Immunogenicity of a Pertussis Outer Membrane Vesicle Vaccine

Wim Jiskoot, PhD
Leiden University Medical Center
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges?

Marieke Van Ham, PhD
Sanquin
CD4 T-cell responses against the therapeutic antibody adalimumab in Rheumatoid Arthritis patients

Kees Melief, PhD
ISA Pharma
Recent Data from ISA Epitope-driven Cancer Vaccine Trials

Laurent Mascarell, PhD
Stallergenes
Biomarkers for Allergy Vaccines

Tom Ottenhoff, MD, PhD
Leiden University Medical Center
Regulatory T cells in Tuberculosis: Friend or Foe?

Prof. Annie De Groot, MD
EpiVax, Inc.
Newest developments on ISPRI immunogenicity prediction tools, de–immunization approaches and Tregitope immuno–modulators
This one-of-a-kind forum for discussion on current approaches in immunogenicity and tolerance induction, with a focus on biologics and vaccines was co-organized with Immuno Valley, Lyon Biopole and MabDesign. The small size of this forum fosters a personal environment where participants engage each other and have the opportunity to connect with the presenters.